SanBio Co (4592.T) Osake Kurssi

SanBio Co Ltd is primarily active in the biotechnology and pharmaceutical industries.

SanBio Co Ltd faces competition from pharmaceutical companies that operate in the regenerative medicine field. Some of the main competitors include Mesoblast Limited, Athersys Inc., and Healios K.K. These companies are also focused on developing innovative therapies for treating neurological disorders and injuries, similar to SanBio. However, SanBio has established its unique position in the market with its proprietary regenerative cell therapy products.

SanBio Co Ltd is a pioneering regenerative medicine company based in Japan. Founded in 2005, SanBio focuses on developing and commercializing groundbreaking cell-based therapies for neurological disorders. With a strong commitment to advancing scientific research, SanBio has made significant strides in neurorehabilitation and regenerative medicine. The company has successfully conducted clinical trials and received approvals from regulatory authorities, demonstrating the effectiveness and safety of its innovative therapies. SanBio's dedication to improving patients' lives through cutting-edge treatments has earned it a prominent position in the field of regenerative medicine.

Some significant milestones achieved by SanBio Co Ltd include the successful completion of Phase II clinical trials for their investigational therapeutic product SB623, which showed promising results in treating motor deficits caused by stroke. Additionally, SanBio Co Ltd received Fast Track designation from the U.S. FDA for SB623, recognizing its potential to address unmet medical needs. The company also expanded its product pipeline and entered into collaborations with global pharmaceutical companies to further advance their regenerative medicine technologies. SanBio Co Ltd continues to strive towards making notable advancements in the field of regenerative medicine and improving patient outcomes.

SanBio Co Ltd is primarily present in Japan.

SanBio Co Ltd represents the values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on advancing regenerative medicine, SanBio is committed to developing novel therapies that address unmet medical needs. By leveraging their proprietary technology, SB623, SanBio aims to restore function and improve the quality of life for patients suffering from neurological disorders. Their dedication to scientific excellence, ethical conduct, and transparency fosters trust among stakeholders. Through their pioneering research and development efforts, SanBio Co Ltd is contributing to advancements in the field of regenerative medicine, bringing hope to patients worldwide.

Analyytikot asettavat tällä hetkellä SanBio Co-osakkeelle keskimääräisen tavoitehinnan 2 091,00 JPY (mediaani: 2 040,00 JPY), mikä merkitsee +140,6 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.

SanBio Co Analyytikkojen kursstavoitteet 2026

11 analyytikkoa arvioi tällä hetkellä SanBio Co-osaketta: 0 suosittaa ostoa, 6 pitoa ja 5 myyntiä.

SanBio Co Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla SanBio Co-osake noteerataan hintaan 4,91 EUR (869,00 JPY).

SanBio Co-osake (4592.T) on listattuna 2 pörssissä, muun muassa: Tokio (JPX) (4592.T).

SanBio Co Ltd is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological diseases. It was originally founded in Japan and its business model includes research and development, clinical trials, partnerships, and distribution. The research and development team at SanBio focuses on developing novel drugs and therapies based on stem cell and genomic research. They utilize state-of-the-art technologies to identify and optimize novel drug candidates to enable successful treatment of neurological diseases. SanBio is committed to conducting clinical trials by partnering with renowned medical centers and research institutions in Japan, the US, and Europe. This collaboration aims to confirm the effectiveness and safety of clinical candidates for broad use in healthcare. SanBio has also formed partnerships with other companies worldwide for the marketing and distribution of its products. These partnerships aim to make SanBio's products and therapies accessible globally. SanBio offers various therapy products for neurological diseases, including "SB623" for traumatic brain injury and "SB509" for Amyotrophic Lateral Sclerosis (ALS). SB623 is being developed to treat patients with skull-brain injuries. It is a cell therapy derived from reprogrammed human neural stem cells from a donor's bone marrow. SB509 is being developed for the treatment of ALS and is a gene therapy that produces neurotrophic factors to promote the survival of motor neurons. Both products have the potential to meet the need for effective therapies for neurological diseases. In summary, SanBio Co Ltd offers innovative therapeutics for the treatment of neurological diseases. The company's business model includes research and development of novel therapies, conducting clinical trials, partnerships, and product distribution. SanBio has the commitment and resources to meet the demand for effective therapeutics for treating neurological diseases.

Liikevaihtoa ei voida laskea SanBio Co:lle tällä hetkellä.

voitto SanBio Co on −3,84 Mrd. JPY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

SanBio Co:n hinta-voitto-suhde (P/E) on tällä hetkellä −17,65. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SanBio Co-osakkeen arvostusta.

P/S-suhdetta ei voida laskea SanBio Co:lle tällä hetkellä.

SanBio Co:n Eulpool-laatuscore on 1/10.

SanBio Co:n ISIN on JP3336750009. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

SanBio Co:n WKN on A14SRH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

SanBio Co:n ticker on 4592.T. Tämä pörssinoteeraus käytetään SanBio Co-osakkeiden kauppaan pörssissä.